Interview: Frans Labuschagne – Head of Pharma, Bayer South Africa
The head of pharma for Bayer Southern Africa reveals how South Africa plays a key role in Bayer’s African strategy, with more than 60 percent of the continent’s total sales,…
Address: 72 Steel Road Spartan , Kempton Park ,South Africa
Tel: +27 11975 0654
Sandoz, the generic pharmaceuticals division of the Novartis Group, is a global leader in the rapidly growing generics industry. With quality going back to its roots in the 19th century, Sandoz has a strong global presence covering 90% of the world’s population. We are committed to providing healthcare products and services of a consistently high standard, worldwide. We believe that consistent and reliable quality is what sets us apart from our competition, by offering customers the safety and efficacy associated with reference medicines, at lower cost.
At Sandoz we make far more than just traditional off-patent medicines. We develop and manufacture a wide range of difficult-to-make medicines, ranging from complex delivery systems for standard generics through to modern biopharmaceutical medicines (biosimilars).
Adhering to one, uniform standard, Sandoz South Africa supplies a comprehensive range of medicines for just about every therapeutic area, from Cardiovascular, Anti-Infectives, CNS, Analgesics, and the challenging field of TB.
Our core business lies in the development, production and distribution of high-quality, affordable generic medicines. We offer approximately 1 000 generic compounds worldwide and are a leading provider of differentiated, value-added products, including state-of-the-art biosimilars, injectables, inhalers and transdermal patches.
The head of pharma for Bayer Southern Africa reveals how South Africa plays a key role in Bayer’s African strategy, with more than 60 percent of the continent’s total sales,…
The CEO of Pharma Dynamics explains why the company was the perfect match for Lupin, as the fastest growing, and largest independently owned acquirable pharmaceutical business in South Africa, why…
The chairman of PHARMISA reveals how pharmaceuticals has been designated as one of eight priority sectors of South African Government’s Industrial Policy Action Plan (IPAP), how South African life expectancy…
The CEO of Pierre Fabre for South Africa reveals how his focus has been on marketing the company brand locally, why the goal of the company is to develop business…
The EO of SAMED discusses recent regulations surrounding the medical device industry in South Africa, why South Africa remains the hub and the major gateway to Africa for medical devices…
The managing director of UTi Pharma reveals how UTi is no longer just an international forwarding company but covers a broad spectrum of activities; why as global business increases it…
The MD of Triclinium Clinical Development discusses how South Africa’s established First and Third World research opportunities and long-established GCP culture have made it a uniquely attractive country for clinical…
The country manager for BMS South Africa talks about the company’s first to market strategy, and how BMS has shifted the treatment paradigm for oncology in South Africa. Through our platform, we introduce the…
Iain Barton reveals how the acquisition of RTT Medical by IHS in 2013 has allowed Imperial to become the biggest pharma supply chain and general logistics services player on the African…
Peter Fuller provides us with an update on the integration of Covidien businesses, and explains how Medtronic is bringing innovation to South African patients and contributing to the improvement of the…
Adv. Leslie Sedibe, CEO of Proudly South African explains how the Proudly South African campaign aims to promote local products and services to ultimately address unemployment, and what his main…
The country president of Novartis South Africa reveals how Novartis has recently moved to new premises, demonstrating a clear commitment to continue investing in the country; why South Africa…
See our Cookie Privacy Policy Here